An integrative healthcare model with heartfulness meditation and care coordination improves outcomes in cyclic vomiting syndrome

2021 ◽  
Author(s):  
Thangam Venkatesan ◽  
Anthony Porcelli ◽  
Anagha Matapurkar ◽  
Vishnu Charan Suresh Kumar ◽  
Aniko Szabo ◽  
...  
Keyword(s):  
Care Coordination ◽  
Cyclic Vomiting Syndrome ◽  
Integrative Healthcare ◽  
Healthcare Model ◽  
Cyclic Vomiting

scholarly journals Cannabinoid hyperemesis syndrome: definition, pathophysiology, clinical spectrum, insights into acute and long-term management

2020 ◽  
Vol 68 (8) ◽  
pp. 1309-1316
Author(s):  
Mahesh Gajendran ◽  
Joshua Sifuentes ◽  
Mohammad Bashashati ◽  
Richard McCallum
Keyword(s):  
Symptom Control ◽  
Well Being ◽  
Clinical Entity ◽  
Cyclic Vomiting Syndrome ◽  
Cannabinoid Hyperemesis Syndrome ◽  
Acute Attacks ◽  
Hot Baths ◽  
Term Management ◽  
Cyclic Vomiting

Although cannabinoid hyperemesis syndrome (CHS) was first reported more than 15 years ago, it still remains an unfamiliar clinical entity among physicians worldwide. CHS is categorized by Rome IV classification as a functional gastroduodenal disorder. It is characterized by stereotypical episodic vomiting in the setting of chronic, daily cannabis use, with cycles decreasing by the cessation of cannabis. CHS is also associated with abdominal pain reduced by hot baths and showers with comparative well-being between attacks. Thus, its clinical presentation resembles ‘classic’ cyclic vomiting syndrome, but eliciting a cannabis history is crucial in diagnosing this entity. In acute attacks, parenteral benzodiazepines are very effective. For prevention and long-term management, tricyclic antidepressants such as amitriptyline are the mainstay of therapy requiring doses in the range of 50–200 mg/d to achieve symptom control. In addition, counseling to achieve marijuana cessation, accompanied by antianxiety medications, is necessary for sustaining clinical outcomes. Once the patient is in remission and off marijuana for a period of 6–12 months, then tapering the dose of amitriptyline can be implemented, with the goal of no therapy being achieved in the majority of patients over time. With the legalization of marijuana in many states, CHS will become an increasingly prevalent clinical entity, so educating about CHS is an important goal, particularly for emergency department physicians who generally first encounter these patients.

CO17 FLUNARIZINE IN THE TREATMENT OF CYCLIC VOMITING SYNDROME (CVS)

2012 ◽  
Vol 44 ◽  
pp. S248
Author(s):  
R. Mallamace ◽  
D. Comito ◽  
S. Cardile ◽  
A. Chiaro ◽  
C. Romano
Keyword(s):  
Cyclic Vomiting Syndrome ◽  
Cyclic Vomiting

Efficacy of Coenzyme Q10 in the Treatment of Cyclic Vomiting Syndrome in Children

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Brezin F ◽  
◽  
Wiedemann A ◽  
Bansept C ◽  
Albuisson E ◽  
...  
Keyword(s):  
Coenzyme Q10 ◽  
Gastrointestinal Disorder ◽  
Cyclic Vomiting Syndrome ◽  
Line Treatment ◽  
First Line ◽  
Excellent Safety Profile ◽  
Third Line ◽  
One Year ◽  
First Line Treatment ◽  
Cyclic Vomiting

Cyclic Vomiting Syndrome (CVS) is a chronic functional gastrointestinal disorder related to migraine, characterized by episodic nausea and vomiting. The treatment of CVS remains based on tricyclic antidepressants, triptans and antiepileptics. As mitochondriopathy has been involved in the pathophysiology of CVS, Coenzyme Q10 (CoQ10), a mitochondrial cofactor, has been used as the third line treatment in CVS. Considering the excellent safety profile of CoQ10, we decided to use it as the first line treatment in CVS. We retrospectively studied the evolution of 23 CVS patients who were treated for one year by CoQ10 alone. We recorded the characteristics of patients and their CVS history and compared data obtained the year before and the year following the prescription of CoQ10 treatment. We found a significant decrease in the number of vomiting episodes between the year before and the year after the start of CoQ10 (median [IQR]: 18.0 [15.75] vs. 3.00 [5.0]; p <0.001). This decrease persisted with time (2 and 3 years of treatment). The treatment was very efficient in 17/23 patients and did not decrease the number of vomiting episodes in 3 patients. Only one mild side effect related to the drug has been reported. Conclusions: CoQ10 is an efficient and safe treatment of CVS and should be used as the first line treatment in this episodic syndrome related to migraine.

scholarly journals Use of a Once-Daily NSAID in Treatment of Cyclic Vomiting Syndrome

2013 ◽  
Vol 29 (3) ◽  
pp. 543-546 ◽  
Author(s):  
Mahesh K. Vidula ◽  
Anil Wadhwani ◽  
Kaleigh Roberts ◽  
Lyle L. Berkowitz
Keyword(s):  
Cyclic Vomiting Syndrome ◽  
Once Daily ◽  
Cyclic Vomiting

Autonomic nerve function in adults with cyclic vomiting syndrome: a prospective study

2010 ◽  
Vol 22 (12) ◽  
pp. 1303-e339 ◽  
Author(s):  
T. Venkatesan ◽  
T. Prieto ◽  
A. Barboi ◽  
B. Li ◽  
A. Schroeder ◽  
...  
Keyword(s):  
Prospective Study ◽  
Autonomic Nerve ◽  
Cyclic Vomiting Syndrome ◽  
Nerve Function ◽  
Autonomic Nerve Function ◽  
A Prospective Study ◽  
Cyclic Vomiting

scholarly journals Emphysematous Gastritis in a Patient with Untreated Cyclic Vomiting Syndrome

2018 ◽  
Vol 5 (1) ◽  
pp. e90
Author(s):  
Sara L. Robinson ◽  
Brett W. Sadowski ◽  
Christa Eickhoff ◽  
Edward Mitre ◽  
Patrick E. Young
Keyword(s):  
Cyclic Vomiting Syndrome ◽  
Emphysematous Gastritis ◽  
Cyclic Vomiting

scholarly journals Emphysematous Gastritis in a Patient with Untreated Cyclic Vomiting Syndrome

2018 ◽  
Vol 5 (12) ◽  
pp. e901-3
Author(s):  
Sara L. Robinson ◽  
Brett W. Sadowski ◽  
Christa Eickhoff ◽  
Edward Mitre ◽  
Patrick E. Young
Keyword(s):  
Cyclic Vomiting Syndrome ◽  
Emphysematous Gastritis ◽  
Cyclic Vomiting

Cannabinoid Receptor Type 1 and mu-Opioid Receptor Polymorphisms Are Associated With Cyclic Vomiting Syndrome

2017 ◽  
Vol 112 (6) ◽  
pp. 933-939 ◽  
Author(s):  
Andrzej Wasilewski ◽  
Urszula Lewandowska ◽  
Paula Mosinska ◽  
Cezary Watala ◽  
Martin Storr ◽  
...  
Keyword(s):  
Opioid Receptor ◽  
Cannabinoid Receptor ◽  
Mu Opioid Receptor ◽  
Receptor Type ◽  
Cyclic Vomiting Syndrome ◽  
Mu Opioid ◽  
Cannabinoid Receptor Type 1 ◽  
Cyclic Vomiting

scholarly journals Cyclic vomiting syndrome: diagnostic approach and current management strategies

2018 ◽  
Vol Volume 11 ◽  
pp. 77-84 ◽  
Author(s):  
William Hayes ◽  
Deidra VanGilder ◽  
Joseph Berendse ◽  
Michael Lemon ◽  
John Kappes
Keyword(s):  
Management Strategies ◽  
Diagnostic Approach ◽  
Cyclic Vomiting Syndrome ◽  
Current Management ◽  
Cyclic Vomiting
Sign in / Sign up

Export Citation Format

Share Document